Intranasal administration of a therapeutic HIV vaccine (Vacc-4x) induces dose-dependent systemic and mucosal immune responses in a randomized controlled trial.

Intranasal administration of a therapeutic HIV vaccine (Vacc-4x) induces dose-dependent systemic and mucosal immune responses in a randomized controlled trial.

Vacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal administration. In this randomized controlled pilot study we investigate intranasal administration of Vacc-4x with Endocine as adjuvant.Safety and immunogenicity were tested in patients...

Full description

Bibliographic Details
Main Authors: Kristin Brekke, Andreas Lind, Carol Holm-Hansen, Inger Lise Haugen, Birger Sørensen, Maja Sommerfelt, Dag Kvale
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4232368?pdf=render

Internet

http://europepmc.org/articles/PMC4232368?pdf=render

Similar Items